ASCO's Quality Training Program

Project Title: Improving the Rate of patient counseling by the pharmacist prior to starting oral oncolytic therapy with capecitabine

Presenters: I. Alex Bowman, MD., Christine Hong, Pharm.D., Mary Gill, Eileen Marley, Pharm. D., BSN., Rebecca Yarborough, MD.

Institution: UT Southwestern Medical Center,
Simmons Comprehensive Cancer Center

Date: 4 October 2017





Institutional Overview: UTSW Simmons Comprehensive Cancer Center

- UT Southwestern Medical Center Hospital Based Clinics
- NCI-designated comprehensive cancer center
- 3 infusion centers: Dallas, Moncrief, Richardson





Problem Statement

Between January and May 2017, only 40.7% (n=11/27) of patients at the Simmons Cancer Center at UT Southwestern were counseled by a UT Southwestern pharmacist prior to the first dose of the oral chemotherapy drug capecitabine, exposing these patients to the risks of toxicity and non-adherence.






Team Members

	Proj	ect Team Members and Roles
Role	Name	Job Function
Project Sponsor#	John Cox, MD	Administrative and Resource Support, Project Guidance
Team Leader+	I. Alex Bowman, MD	Project organization and leadership; MD input for workflow/process at PHHS and SCCC
Core Team Member*	Jieun Christine Hong, Pharm.D. MBA	SCC Pharmacy Input and organization, implementation of changes to pharmacy practices at PHHS
Core Team Member*	Eileen Marley, PharmD, BCOP	PMMH Pharmacy Input and organization, implementation of changes to pharmacy practices at PHHS
Facilitator	Amanda Shaughnessy	Team member who facilitates the team meetings to optimize group processes.
Core Team Member*	Rebecca Yarborough, MD	MD input for workflow/process at PHHS
Core Team Member*	Mary Gill, BSN	SCCC Clinic and RN Input
Other Team Member^	Donna Bryant, MSN, ANP-BC, OCN	SCCC Clinic and RN Input
Other Team Member^	Thanh Bui	SCCC Pharmacy Input
Core Team Member*	Susan Chacko, PharmD, BCOP	SCCC Pharmacy Input
Patient/ Family Member	Pending	
QTP Improvement Coach	Beverly Hardy-Decuir	Provides remote support to the team regarding the science of quality improvement and participation in the QTP.





Process Map










Process Map

TRAINING PROGRAM™



American Society of Clinical Oncology


Diagnostic Data

- GI Clinic Observation
- Pharmacy-specific process mapping
- Workflow analysis of pharmacy process (pending)







Process Map – GI Clinic



Process Map – Pharmacy



Process Map – Pharmacy



Cause & Effect Diagram

Clinic **Process** Resources Lack of a well defined system-No standardized work-flow for Pharmacy staff not available at time of visit education by clinic providers wide patient education plan Who is responsible for Clinic fails to notify pharmacy Insufficient pharmacy staff to counsel all counseling is not well defined of new medications starts patients Pharmacy is not integrated into High (and increasing) volume of clinic work-flow patients require counseling Medication started urgently EMR med registry is not user friendly Late appointments may not allow time for post-visit EMR med registry does not counseling No patient allow tracking of new start Patient may be discharged from prescriptions counseling by clinic before counseling has **UTSW** occurred pharmacy prior to first dose of Lack of perceived importance of counseling medication Patient unable or unwilling to come for Treatment delayed due to separate counseling visit illness/procedure Patient unable to afford medication or PAP Patient difficult to reach by phone not available Patient already counseled by outside UTSW MD prescribed directly to outside pharmacy pharmacy Continuation of medication initially prescribed Patient leaves clinic prior to recommended by outside provider counseling Prescription not filled at UTSW pharmacy **Patient Med Access**

American Society of Clinical Oncology

Aim Statement

From August 1st through September 30th, 90% of patients prescribed capecitabine for the treatment of oncology indication will be counseled by a UTSW pharmacist prior to taking the first dose of their medication.





Measures

- Measure:
 - Number of new prescriptions for capecitabine during specified period
 - Number of prescription filled at UTSW vs. non-UTSW pharmacy location
 - Actual medication start date of administration
 - Method of counseling performed
 - Turnaround time to obtain prescription, counseling and start of medication by the patient
- Patient population:
 - All patients newly starting on capecitabine treatment
 -Exclusion: none
- Data source:
 - EPIC® HER, Pioneer®, documented patient reported data
- Data collection frequency: baseline and biweekly
- Data quality(any limitations):
 - patient reported data: date of first dose taken, prescription filled at non-UTSW pharmacy

American Society of Clinical Oncology





Age	
1	age 30-39
6	age 40-49
6	age 50-59
8	age 60-69
5	age 70-79
1	age 80-89
Gender	
5	Male
22	Female
Diagnosis	
15	Breast cancer
11	GI
1	Other

Race	
19	White
7	Black
1	Other
Ethnicity	
4	Hispanic
23	Non-Hispanic



















Prioritized List of Changes (Priority/Pay – Off Matrix)

	- Identify/Assign responsibilities for patient education	- Develop a pathway within the EMR to rapidly identify and prioritize patients requiring initial education
High	- Develop standardized educational material	- Dedicate pharmacy staff to early patient education (in person if possible)
act	- Educate providers on availability and importance of pharmacy education	- Obtain dedicated clinical space for in- person counseling
Impact		- Standardize documentation for pharmacy education encounters
Low		- Coordinate release of Rx to outside pharmacy with plan for SCC pharmacist education







PDSA Plan (Test of Change)

Date of PDSA Cycle	Description of Intervention	Results	Action Steps
8-17-17 – 8/29/17	Go-live date for EMR filtering	1. (n) pts counseled, (n) rx written2. Identified difficulties with use of EMR filtering	1. Routine engagement with IR (information resoureces)
8-30-17	Continued discussion with IR to optimize EMR	1. (n) pts counseled, (n) rx written2. Continued refinement of filtering process	1. Need for better ways to filter out inappropriate patients and manage completed work.
9-13-17 Continued discussion with IR to optimize EMR		1. (n) pts counseled, (n) rx written2. Continued refinement of filtering process	 Pharmacy workflow observation planned Pharmacy to document ideal workflow

American Society of Clinical Oncology

Materials Developed

Patient instructions:

Administration: Take capecitabine	by mouth twice a day with meals approximately 12 hours apar
within 30 min of meals, for 14 days on,7 days of	ff. Patient to start on
Missed doses: If you miss a dose, take it as soo	n as you remember. If almost time for your next dose, skip the
missed dose. Do not take extra medication to m	nake up for the missed dose.
Medication adherence: Make sure to take cape	ecitabine as instructed to get the maximum benefit out of the
medication. As discussed you can use calendar	and/or pill box to help with medication adherence.
Safe handling: Wear gloves when touching this	medication or use medication cup to put the drug into and then
take it Wash your hands before & after	

Side effects and management:

- Diarrhea: Take Imodium A.D (<u>loperamide</u>)- 2 tablets at onset of diarrhea, then 1 ta
 until diarrhea stops. May take up to 8 tablets in a 24 hour period if needed. Avoid
 milk products and cruciferous vegetables such as Brussel sprouts and broccoli. Try
 applesauce, toast) and clear liquid as a starting point. Eventually, pasta without sau
 without skin, scrambled eggs and other easily digested foods can be added, as tole
 (water and/or Gatorade).
- Nausea and vomiting: Take your anti-nausea medicine. Take small sips of water du
 hard to drink a full glass at one time. Eat 5 or 6 small meals during the day, instead
- Mouth sores: Clean mouth gently, use soft-bristle tooth brush. Rinse mouth with sobaking soda, 1/8 tsp salt and 1 cup warm water mix) three times daily after meals.
 crunchy foods. Don't drink orange, lemon, tomato, or grapefruit juice
- Fatigue: Perform mild activity regularly as tolerated & take frequent breaks in bety
- Hand-Foot Syndrome (HFS): Limit exposure of hands and feet to hot water when we Cool your hands and feet with ice packs or cool running water or compresses. Gent (eg. Udderly Smooth, Cetaphil cream) to keep your hands moist. Use soft slippers. Unnecessary force or friction (rubbing) on the hands or feet

- Please call clinic right away for:

- Signs of an infection such as fever (over 100.4ºF or 38ºC by an oral thermometer); chills; cough; pain or burning when you pass urine.
- o Signs of bleeding problems such as black tarry stools; blood in urine; pinpoint red spots on skin.
- Signs of heart or lung problems such as fast or uneven heartbeat, chest pain, chest pressure, shortness of breath or difficulty in breathing, swelling of ankles, or fainting.
- Signs of an allergic reaction (rare) soon after a treatment including dizziness, fast <u>heart beat</u>, face swelling, or breathing problems.
- Seizures or loss of consciousness with or without confusion, headache, or changes in eyesight.

- Please contact your clinic for painful hand-foot skin reaction, diarrhea>4 stools per day than usual, nausea/vomiting, sores in mouth, yellowing of skin, unusual weakness or severe abdominal /stomach cramping/pain, or other bothersome side effects.

Medication reconciliation: If any new medications are added into your therapy or discontinued or dose changes, please inform the clinic/pharmacy. Please check with your doctor or pharmacist before taking any new medications including over-the-counter medications/herbal supplements.

Storage: <u>Capecitabine</u> tablets should be kept out of the reach of children, at room temperature, away from heat, light and moisture

Medication disposal: Return any unused medications or empty <u>capecitabine</u> bottles to pharmacy for safe disposal. **Refills:** Please call your pharmacy at least one week before you run out of your medication for a refill, or if any side effects, please call physician's office first before ordering additional refills.

Appointments: Keep all appointments for lab work and physician/radiation visits as scheduled. Next MD appointment is on_____





Materials Developed: Patient Survey

Medication Therapy Management Clinic and Financial Assistance Program Patier	nt Survey	
I am aware of the pharmacist oral chemotherapy education program at the Simmons	Υ	N
Comprehensive Cancer Center.		
I learned something new about my medication(s) by discussing with the pharmacist.	Y	N
I understand my medication better after discussing with the pharmacist.	Υ	N
I am aware of the medication co-pay assistance program.	Y	N
I understand the benefits of applying for a co-pay assistance program.	Y	N
It is convenient to use Simmons Retail Pharmacy for my prescriptions.	Y	N
I feel safer and more confident taking my medication after discussing it with the pharmacy.	Y	N





Materials Developed: Registry List

Current oral oncolytic medication registry list


Age	Sex	Oral Rx Med	Last Ordered On	Admitted	Last Onc Visit	, Next Onc Visit	Last MTM Visit	Last MTM Contact	Next N Next MTM Outreach Specialty Comments
48y/o	Male	capecitabine 500 mg oral tablet	09/19/2017		09/19/2017	10/05/2017			Not Specified
90y/o	Male	capecitabine 500 mg oral tablet	07/19/2017		07/17/2017			07/27/2017	Not Specified
67y/o	Male	thalidomide 50 mg oral capsule	09/25/2017		08/31/2017	10/05/2017			Not Specified
73y/o	Male	cyclophosphamide 50 mg oral capsule	09/20/2017		09/25/2017	10/23/2017			Not Specified
53y/o	Female	erlotinib (TARCEVA) 100 mg oral tablet	10/02/2017		10/02/2017	11/02/2017			Not Specified
36y/o	Female	palbociclib 125 mg Cap	09/21/2017		09/21/2017	10/09/2017			Not Specified
46y/o	Male	trifluridine-tipiracil 15-6.14 mg Tab	09/07/2017		08/29/2017	10/05/2017		09/20/2017	Not Specified
41y/o	Male	temozolomide 140 mg oral capsule	09/19/2017		09/19/2017				Not Specified
68y/o	Male	SUNItinib 50 mg oral capsule	08/29/2017		09/14/2017	10/05/2017			Not Specified

Patient Name and MRN removed





Materials Developed: MTM Template







Materials Developed: MTM Template

Reasons for Non-Adherence					
no proble	ms identified		a	dverse effects	
fin	ancial	instru	instructed by provider to hold or take differently		
lack of per	t	language barrier			
low hea	low health literacy			atient forgets	
knowle	dge deficit		р	atient refuses	
psyc	hosocial		no	transportation	
Other Non-Adherence Re	eason				
Adherence Tools Used					
alarm		ca	alendar		
cell phon	e	directe	d education		
keychain pill o	carrier	medication dosir	ng chart or ca	alculator	
medication	list	р	ill box		
watch					
Other Adherence Tool					
Support Network for Adheren					
family member	healthcare	provider home heal	th agency		
Other Support Network					
Confirmed Plan for Next Med	ication Refill				
delivery by pharmacy	pick-up at	pharmacy outside	e pharmacy	not applicable	
Refills Needed for Supportive	Medications				
yes, ordered or provide	er notified	not needed			
D		Tr.			
Pa	tient Coun	seling			
C	ounseled the F	atient on the Following			
		adherence/missed doses		cost of medications/cost implications	
		doses and administration		lab monitoring/follow-up	
	ph	armacy contact information	on	possible adverse effects and management	
	possible drug/OTC drug and food interactions			possible drug/Rx drug interactions	
	safe handling, storage, and disposal			therapeutic rationale	
	use of contraception				
	Marie and the second second				
	Other Topic				
	Other Topic				
To		t Counseling Patient			





Materials Developed: Marketing

What is the Medication Management Clinic?

- Medication adherence and monitoring is very important while you are on treatment. We provide Adherence Management and patient monitoring for safety and efficacy.
- Pharmacist will meet with you to review your medications and offer education to answer your questions and help you to manage your medication treatment and potential side effects.
- Pharmacists will reach out to you monthly to check in on you and remind you to refill your medications. We work
 closely with your doctor to stay current about your medication therapy management though using same electronic
 medical record.


What does the Oncology Retail Pharmacy Services at UTSW Simmons Cancer Center Offer?

- Pharmacists work closely with your doctors and other caregivers to ensure your medication therapy is safe and effective
- Pharmacists can access your electronic medical record, including your medical history and medication records so that we can ensure your specialty drugs works well with your other medications. We can also communicate and follow up with your Doctor to help minimize any side-effects that you might be experiencing.





Change Data: Post Intervention







Conclusions

- The proportion of patients counseled by a UTSW pharmacist prior to starting capecitabine improved from 40.7% (Jan – May) to 62.8% (June – Sept 2017).
- 22.1% absolute improvement since project implementation
 - 37% reduction in patients not receiving counseling anytime prior to starting
 - 57% increase (0/27 -> 20/35) in patients receiving counseling before the first day on their medication
- Interventions:
 - EMR filter optimization discussion
 - Pharmacists awareness to focus on capecitabine patients
 - Verbal communication to insure patients are monitored
 - New education tools developed
- Require workflow analysis by the IR analyst to develop a tool that can be utilized by the pharmacist to triage daily workflow more efficiently





Next Steps/Plan for Sustainability

- Continue to refine EMR filtering process to rapidly and reliably identify patients appropriate for pharmacy counseling
 - Workflow analysis of pharmacy counseling process
 - Possible migration to a work-que or referral-based system for pharmacist notification
- Incorporation of specialty pharmacy medication
- Incorporation with an existing BMT pharmacy education program
- Analysis of resources required for Capecitabine MTM and make appropriate requests for additional staffing/funding/clinic space required for expansion
- Eventual expansion to all oral oncolytic medications



